First Annual Conference on CNS Clinical Trials,
Co-Sponsored by SNO and ASCO
October 1-2, 2021
A Virtual Conference
Now Accepting Abstract Submissions
Abstract Deadline: July 12, 2021, at 11:59 pm EDT
Announcing the First Annual Conference on CNS Clinical Trials, Co-sponsored by SNO and ASCO, being held virtually Friday, October 1 - Saturday, October 2, 2021. The goal of this annual Conference is to provide a deeper dive into the area of neuro-oncology clinical trials to understand how we can make more significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.
This collaborative conference will address the needs of patients with glioblastoma and intracranial malignancy in general, both primary and secondary, and stimulate clinical research in these areas of great unmet clinical need. Research advocating new approaches, out of the box ideas and reforms in the area of neuro-oncology clinical trials will be presented and discussed. The structure will provide a forum that cuts across a large breadth of disciplines and emphasizes aspects of clinical trial design, statistics and interpretation of trial outcomes to develop a better understanding of why numerous glioblastoma and other neuro-oncology clinical trials do not achieve their ultimate objective of prolonging survival of patients and other meaningful clinical measures. In addition, it will provide a forum that promotes collaboration and cross-fertilization of novel ideas between those invested in the care of patients with primary and secondary malignancies of the CNS.
- Explain how to apply current and emerging data collected from both systemic and local therapies to future novel clinical trials for patients with primary and metastatic cancers of the CNS.
- Describe novel approaches such as synthetic control arms and use of big data in optimal clinical trial design for patients with primary and metastatic cancers of the CNS.
- Compare novel imaging platforms that assess both response assessment and differentiation of tumor vs treatment effect, and their potential therapeutic applications for patients with primary and metastatic cancers of the CNS.
- Identify strategies to integrate supportive and palliative care into the care of patients with primary and metastatic cancers of the CNS.
Registration for the conference will open soon.
Who should attend
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials.
The organizers of the Conference welcome the submission of original research and clinical findings addressing CNS clinical trials. All submissions will be peer-reviewed, and accepted abstracts will be presented as oral talks or electronic posters. Accepted abstracts will be published and indexed in Neuro-Oncology Advances
. Abstract submission categories are listed below:
- Systemic Therapeutics (e.g. Targeted, ADC, Cytotoxic)
- Local Therapies (e.g. Surgery, Radiation, LITT, others)
- Immunotherapy (e.g. Car-T cell, Oncolytic Viruses)
- Clinical Research Methods (e.g. Trial Design, Molecular Correlatives, Big Data)
- Supportive Care and Survivorship (e.g. Neurocognition, QoL, Palliative Care)
- Neuroimaging (Diagnostic and Therapeutic Applications/Endpoints in Trials)
To submit an abstract, click here
. The organizers will accept encore clinical trials abstracts, including trials in progress. For more information, please click here
Abstracts must be received by the submission deadline of Tuesday, July 12, 2021, 11:59 pm EDT
Program Committee Co-Chairs
Carey Anders, Duke University
Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto
Program Committee Co-Chairs Elect
Priscilla Brastianos, Massachusetts General Hospital
Mustafa Khasraw, Duke University
Evanthia Galanis, Mayo Rochester
Sarah Goldberg, Yale University
Sara Hurvitz, University of California, Los Angeles
Rupesh Kotecha, Miami Cancer Institute
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Alireza Mansouri, Penn State Cancer Institute
Minesh Mehta, Miami Cancer Institute
Michael Platten, Medical Faculty Mannheim
Mei-Yin C. Polley, University of Chicago and NRG Oncology
Solmaz Sahebjam, Moffitt Cancer Center
Hussein Tawbi, MD Anderson Cancer Center